These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34714686)

  • 21. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Khanam F; Babu G; Rahman N; Liu X; Rajib NH; Ahmed SU; Hossen MI; Biswas PK; Kelly S; Thesis-Nyland K; Mujadidi Y; McMillan NAJ; Pollard AJ; Clemens JD; Qadri F
    Vaccine; 2023 May; 41(19):3137-3140. PubMed ID: 37061369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A; Pakkanen SH; Karttunen R; Kantele JM
    PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
    Pakkanen SH; Kantele JM; Rombo L; Kantele A
    Scand J Immunol; 2017 Oct; 86(4):207-215. PubMed ID: 28675263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
    Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.
    Marshall JL; Flores-Langarica A; Kingsley RA; Hitchcock JR; Ross EA; López-Macías C; Lakey J; Martin LB; Toellner KM; MacLennan CA; MacLennan IC; Henderson IR; Dougan G; Cunningham AF
    J Immunol; 2012 Dec; 189(12):5527-32. PubMed ID: 23162127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A
    Jones E; Jin C; Stockdale L; Dold C; Pollard AJ; Hill J
    Microorganisms; 2021 Jun; 9(7):. PubMed ID: 34203328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of Typhi Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency.
    Evans C; Bateman E; Steven R; Ponsford M; Cullinane A; Shenton C; Duthie G; Conlon C; Jolles S; Huissoon AP; Longhurst HJ; Rahman T; Scott C; Wallis G; Harding S; Parker AR; Ferry BL
    Clin Exp Immunol; 2018 Jun; 192(3):292-301. PubMed ID: 29377063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.
    Acharya IL; Lowe CU; Thapa R; Gurubacharya VL; Shrestha MB; Cadoz M; Schulz D; Armand J; Bryla DA; Trollfors B
    N Engl J Med; 1987 Oct; 317(18):1101-4. PubMed ID: 3657877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Honda-Okubo Y; Cartee RT; Thanawastien A; Seung Yang J; Killeen KP; Petrovsky N
    Vaccine; 2022 Jul; 40(32):4625-4634. PubMed ID: 35750538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine.
    Saxena M; Di Fabio JL
    Vaccine; 1994 Aug; 12(10):879-84. PubMed ID: 7526567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization.
    Keddy KH; Klugman KP; Hansford CF; Blondeau C; Bouveret le Cam NN
    Vaccine; 1999 Jan; 17(2):110-3. PubMed ID: 9987143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
    Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
    Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of active component US military personnel against Salmonella Typhi.
    Porter CK; Sorrell T; Mitra I; Riddle MS
    Vaccine; 2017 Mar; 35(14):1742-1748. PubMed ID: 28268075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
    Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
    Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salmonella Typhi outer membrane protein STIV is a potential candidate for vaccine development against typhoid and paratyphoid fever.
    Das S; Chowdhury R; Pal A; Okamoto K; Das S
    Immunobiology; 2019 May; 224(3):371-382. PubMed ID: 30952553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay.
    Rijpkema S; Durrani Z; Lemercinier X; Jones C
    Biologicals; 2004 Mar; 32(1):11-6. PubMed ID: 15026021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
    Szu SC; Taylor DN; Trofa AC; Clements JD; Shiloach J; Sadoff JC; Bryla DA; Robbins JB
    Infect Immun; 1994 Oct; 62(10):4440-4. PubMed ID: 7927707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.